How p53 Affects Cancer Cell Resistance to Drugs
Author Information
Author(s): Galmarini C M, Falette N, Tabone E, Levrat C, Britten R, Voorzanger-Rousselot N, Roesch-Gateau O, Vanier-Viornery A, Puisieux A, Dumontet C
Primary Institution: INSERM 453, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller
Hypothesis
The study investigates the role of p53 in the sensitivity of cancer cells to tubulin-binding agents.
Conclusion
The p53 status of cancer cells significantly influences their sensitivity to tubulin-binding agent cytotoxicity.
Supporting Evidence
- The MDD2 cell line was significantly more resistant to the cytotoxic effects of vinblastine and paclitaxel than the MN1 cell line.
- MN1 cells displayed wild-type p53 protein accumulation after exposure to tubulin-binding agents.
- Exposure of MN1 cells to tubulin-binding agents resulted in more apoptosis compared to MDD2 cells.
Takeaway
This study shows that cancer cells with a normal p53 gene are more sensitive to certain cancer drugs than those with a mutated p53 gene.
Methodology
The study compared drug sensitivity, cell cycle distribution, and drug-induced apoptosis in two MCF-7 cell lines with different p53 statuses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website